Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies

Abstract There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immun...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.) Fla.), 2010-05, Vol.135 (2), p.255-263
Hauptverfasser: Yong, Pierre L, Boyle, John, Ballow, Mark, Boyle, Marcia, Berger, Melvin, Bleesing, Jack, Bonilla, Franciso A, Chinen, Javier, Cunninghamm-Rundles, Charlotte, Fuleihan, Ramsay, Nelson, Lois, Wasserman, Richard L, Williams, Kathleen C, Orange, Jordan S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 263
container_issue 2
container_start_page 255
container_title Clinical immunology (Orlando, Fla.)
container_volume 135
creator Yong, Pierre L
Boyle, John
Ballow, Mark
Boyle, Marcia
Berger, Melvin
Bleesing, Jack
Bonilla, Franciso A
Chinen, Javier
Cunninghamm-Rundles, Charlotte
Fuleihan, Ramsay
Nelson, Lois
Wasserman, Richard L
Williams, Kathleen C
Orange, Jordan S
description Abstract There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.
doi_str_mv 10.1016/j.clim.2009.10.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877571006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661609008432</els_id><sourcerecordid>877571006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2326-a5afd67b1ef9d01de63458f2c9ed56e2c094fe81844ad149cd9ba489f219a1f43</originalsourceid><addsrcrecordid>eNp9UU1LxDAQLaLguvoHPPXmaeskbdMGRBDxCxY86J5DNploapuuSbuw_97U3ZMHD0Mmw3uPeW-S5JJARoCw6yZTre0yCsDjIAPIj5IZKSlZVJCXx4eeMcJOk7MQGgAoKWWzxK4Cpr1JrRu83KLrx5Darhtd_9H267G1LpVOp1I3o1OD3WI6fKKXG4sR56ZPOniUQ4dumHQ23nbS7w4aGo1VFl2scJ6cGNkGvDi882T1-PB-_7xYvj693N8tF4rmlC1kKY1m1Zqg4RqIRpYXZW2o4qhLhlQBLwzWpC4KqUnBleZrWdTcUMIlMUU-T672uhvff48YBtHZoLBtpcPoTtRVVVYEgEUk3SOV70PwaMRhe0FATLGKRkyxiinWaRZjjaSbPQmjh61FL8KvQ9TWoxqE7u3_9Ns_9AhxVsn2C3cYmn70LqYjiAhUgHib7jadDThAXeQ0_wFBqpiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>877571006</pqid></control><display><type>article</type><title>Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies</title><source>Access via ScienceDirect (Elsevier)</source><creator>Yong, Pierre L ; Boyle, John ; Ballow, Mark ; Boyle, Marcia ; Berger, Melvin ; Bleesing, Jack ; Bonilla, Franciso A ; Chinen, Javier ; Cunninghamm-Rundles, Charlotte ; Fuleihan, Ramsay ; Nelson, Lois ; Wasserman, Richard L ; Williams, Kathleen C ; Orange, Jordan S</creator><creatorcontrib>Yong, Pierre L ; Boyle, John ; Ballow, Mark ; Boyle, Marcia ; Berger, Melvin ; Bleesing, Jack ; Bonilla, Franciso A ; Chinen, Javier ; Cunninghamm-Rundles, Charlotte ; Fuleihan, Ramsay ; Nelson, Lois ; Wasserman, Richard L ; Williams, Kathleen C ; Orange, Jordan S</creatorcontrib><description>Abstract There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2009.10.003</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Allergy and Immunology ; Antibiotic prophylaxis ; Antibiotics ; Best practice ; Complementary and alternative medicine ; hygiene ; Intravenous immunoglobulin ; Primary immunodeficiency ; Subcutaneous immunoglobulin</subject><ispartof>Clinical immunology (Orlando, Fla.), 2010-05, Vol.135 (2), p.255-263</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2326-a5afd67b1ef9d01de63458f2c9ed56e2c094fe81844ad149cd9ba489f219a1f43</citedby><cites>FETCH-LOGICAL-c2326-a5afd67b1ef9d01de63458f2c9ed56e2c094fe81844ad149cd9ba489f219a1f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2009.10.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Yong, Pierre L</creatorcontrib><creatorcontrib>Boyle, John</creatorcontrib><creatorcontrib>Ballow, Mark</creatorcontrib><creatorcontrib>Boyle, Marcia</creatorcontrib><creatorcontrib>Berger, Melvin</creatorcontrib><creatorcontrib>Bleesing, Jack</creatorcontrib><creatorcontrib>Bonilla, Franciso A</creatorcontrib><creatorcontrib>Chinen, Javier</creatorcontrib><creatorcontrib>Cunninghamm-Rundles, Charlotte</creatorcontrib><creatorcontrib>Fuleihan, Ramsay</creatorcontrib><creatorcontrib>Nelson, Lois</creatorcontrib><creatorcontrib>Wasserman, Richard L</creatorcontrib><creatorcontrib>Williams, Kathleen C</creatorcontrib><creatorcontrib>Orange, Jordan S</creatorcontrib><title>Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies</title><title>Clinical immunology (Orlando, Fla.)</title><description>Abstract There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.</description><subject>Allergy and Immunology</subject><subject>Antibiotic prophylaxis</subject><subject>Antibiotics</subject><subject>Best practice</subject><subject>Complementary and alternative medicine</subject><subject>hygiene</subject><subject>Intravenous immunoglobulin</subject><subject>Primary immunodeficiency</subject><subject>Subcutaneous immunoglobulin</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9UU1LxDAQLaLguvoHPPXmaeskbdMGRBDxCxY86J5DNploapuuSbuw_97U3ZMHD0Mmw3uPeW-S5JJARoCw6yZTre0yCsDjIAPIj5IZKSlZVJCXx4eeMcJOk7MQGgAoKWWzxK4Cpr1JrRu83KLrx5Darhtd_9H267G1LpVOp1I3o1OD3WI6fKKXG4sR56ZPOniUQ4dumHQ23nbS7w4aGo1VFl2scJ6cGNkGvDi882T1-PB-_7xYvj693N8tF4rmlC1kKY1m1Zqg4RqIRpYXZW2o4qhLhlQBLwzWpC4KqUnBleZrWdTcUMIlMUU-T672uhvff48YBtHZoLBtpcPoTtRVVVYEgEUk3SOV70PwaMRhe0FATLGKRkyxiinWaRZjjaSbPQmjh61FL8KvQ9TWoxqE7u3_9Ns_9AhxVsn2C3cYmn70LqYjiAhUgHib7jadDThAXeQ0_wFBqpiA</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Yong, Pierre L</creator><creator>Boyle, John</creator><creator>Ballow, Mark</creator><creator>Boyle, Marcia</creator><creator>Berger, Melvin</creator><creator>Bleesing, Jack</creator><creator>Bonilla, Franciso A</creator><creator>Chinen, Javier</creator><creator>Cunninghamm-Rundles, Charlotte</creator><creator>Fuleihan, Ramsay</creator><creator>Nelson, Lois</creator><creator>Wasserman, Richard L</creator><creator>Williams, Kathleen C</creator><creator>Orange, Jordan S</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20100501</creationdate><title>Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies</title><author>Yong, Pierre L ; Boyle, John ; Ballow, Mark ; Boyle, Marcia ; Berger, Melvin ; Bleesing, Jack ; Bonilla, Franciso A ; Chinen, Javier ; Cunninghamm-Rundles, Charlotte ; Fuleihan, Ramsay ; Nelson, Lois ; Wasserman, Richard L ; Williams, Kathleen C ; Orange, Jordan S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2326-a5afd67b1ef9d01de63458f2c9ed56e2c094fe81844ad149cd9ba489f219a1f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Allergy and Immunology</topic><topic>Antibiotic prophylaxis</topic><topic>Antibiotics</topic><topic>Best practice</topic><topic>Complementary and alternative medicine</topic><topic>hygiene</topic><topic>Intravenous immunoglobulin</topic><topic>Primary immunodeficiency</topic><topic>Subcutaneous immunoglobulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yong, Pierre L</creatorcontrib><creatorcontrib>Boyle, John</creatorcontrib><creatorcontrib>Ballow, Mark</creatorcontrib><creatorcontrib>Boyle, Marcia</creatorcontrib><creatorcontrib>Berger, Melvin</creatorcontrib><creatorcontrib>Bleesing, Jack</creatorcontrib><creatorcontrib>Bonilla, Franciso A</creatorcontrib><creatorcontrib>Chinen, Javier</creatorcontrib><creatorcontrib>Cunninghamm-Rundles, Charlotte</creatorcontrib><creatorcontrib>Fuleihan, Ramsay</creatorcontrib><creatorcontrib>Nelson, Lois</creatorcontrib><creatorcontrib>Wasserman, Richard L</creatorcontrib><creatorcontrib>Williams, Kathleen C</creatorcontrib><creatorcontrib>Orange, Jordan S</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yong, Pierre L</au><au>Boyle, John</au><au>Ballow, Mark</au><au>Boyle, Marcia</au><au>Berger, Melvin</au><au>Bleesing, Jack</au><au>Bonilla, Franciso A</au><au>Chinen, Javier</au><au>Cunninghamm-Rundles, Charlotte</au><au>Fuleihan, Ramsay</au><au>Nelson, Lois</au><au>Wasserman, Richard L</au><au>Williams, Kathleen C</au><au>Orange, Jordan S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><date>2010-05-01</date><risdate>2010</risdate><volume>135</volume><issue>2</issue><spage>255</spage><epage>263</epage><pages>255-263</pages><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>Abstract There are an expanding number of primary immunodeficiency diseases (PIDDs), each associated with unique diagnostic and therapeutic complexities. Limited data, however, exist supporting specific therapeutic interventions. Thus, a survey of PIDD management was administered to allergists/immunologists in the United States to identify current perspectives and practices. Among 405 respondents, the majority of key management practices identified were consistent with existing data and guidelines, including the provision of immunoglobulin therapy, immunoglobulin dosing and selective avoidance of live viral vaccines. Practices for which there are little specific data or evidence-based guidance were also examined, including evaluation of IgG trough levels for patients receiving immunoglobulin, use of prophylactic antibiotics and recommendations for complementary/alternative medicine. Here, variability applied to PIDD patients was identified. Differences between practitioners clinically focused upon PIDD and general allergists/immunologists were also identified. Thus, a need for expanded clinical research in PIDD to optimize management and potentially improve outcomes was defined.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.clim.2009.10.003</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1521-6616
ispartof Clinical immunology (Orlando, Fla.), 2010-05, Vol.135 (2), p.255-263
issn 1521-6616
1521-7035
language eng
recordid cdi_proquest_miscellaneous_877571006
source Access via ScienceDirect (Elsevier)
subjects Allergy and Immunology
Antibiotic prophylaxis
Antibiotics
Best practice
Complementary and alternative medicine
hygiene
Intravenous immunoglobulin
Primary immunodeficiency
Subcutaneous immunoglobulin
title Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A37%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20intravenous%20immunoglobulin%20and%20adjunctive%20therapies%20in%20the%20treatment%20of%20primary%20immunodeficiencies&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Yong,%20Pierre%20L&rft.date=2010-05-01&rft.volume=135&rft.issue=2&rft.spage=255&rft.epage=263&rft.pages=255-263&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2009.10.003&rft_dat=%3Cproquest_cross%3E877571006%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=877571006&rft_id=info:pmid/&rft_els_id=S1521661609008432&rfr_iscdi=true